Neurocrine halts development of schizophrenia drug as trial fails
페이지 정보
작성자 Lloyd 댓글 0건 조회 36회 작성일 24-09-28 11:10본문
Sept 12 (Reuters) - Neurocrine Biosciences said on Thursday it will halt the development of its experimental drug, aimed at improving cognitive function buy neurocaine powder in bulk usa patients with schizophrenia, after it did not achieve the primary goal in a mid-stage trial.
The company said the drug, luvadaxistat, did not replicate the results from a previous mid-stage trial that showed improved cognitive performance, due to a large variability in the cognitive measures across the patients and a potential imbalance in their baseline characteristics.
In the previous study, luvadaxistat failed to meet the main goal of change from baseline in negative symptoms of schizophrenia, however, it met the secondary goal of improving cognitive performance.
Neurocrine said it will focus its resources on late-stage development of its other schizophrenia and depression drug candidates.
Shares of the company were down 2.5% in extended trading.
Last month, the company said its other schizophrenia drug, NBI-1117568, helped reduce the severity of symptoms in a mid-stage trial, but there were concerns whether the benefit could be replicated buy neurocaine powder in bulk usa larger trials.
If you beloved this informative article in addition to you would want to obtain more info about buy neurocaine powder online usa i implore you to go to the website. (Reporting by Puyaan Singh; Editing by Mohammed Safi Shamsi and Shinjini Ganguli)
The company said the drug, luvadaxistat, did not replicate the results from a previous mid-stage trial that showed improved cognitive performance, due to a large variability in the cognitive measures across the patients and a potential imbalance in their baseline characteristics.
In the previous study, luvadaxistat failed to meet the main goal of change from baseline in negative symptoms of schizophrenia, however, it met the secondary goal of improving cognitive performance.
Neurocrine said it will focus its resources on late-stage development of its other schizophrenia and depression drug candidates.
Shares of the company were down 2.5% in extended trading.
Last month, the company said its other schizophrenia drug, NBI-1117568, helped reduce the severity of symptoms in a mid-stage trial, but there were concerns whether the benefit could be replicated buy neurocaine powder in bulk usa larger trials.
If you beloved this informative article in addition to you would want to obtain more info about buy neurocaine powder online usa i implore you to go to the website. (Reporting by Puyaan Singh; Editing by Mohammed Safi Shamsi and Shinjini Ganguli)
댓글목록
등록된 댓글이 없습니다.
